Navigation Links
PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
Date:2/25/2008

BOSTON, Feb. 25 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services provider, will present on key topics at the Drug Information Association's (DIA) 20th Annual EuroMeeting in Barcelona, Spain being held March 3 - 5, 2008. Attendees will benefit from presentations by some of PAREXEL's thought leaders, selected by the DIA to address industry issues including pharmacovigilance, globalization of clinical trials, data-driven patient recruitment, non-interventional studies, gene therapy regulations, combination products, biosimilars, and cosmeceuticals.

PAREXEL experts will present or chair the following sessions:

Monday, March 3

-- Pharmacovigilance and Medical Writing View With Emphasis on Practical

Solutions to the Pitfalls and Grey Areas (tutorial) - Alison Rapley,

Director, Medical Writing Services, Europe, Clinical Research Services

(9:00)

-- Navigating the Gene Therapy Regulations for Clinical Trials -- Cecil

Nick, Principal Consultant, PAREXEL Consulting

(11:00)

Tuesday, March 4

-- Globalization of Clinical Trials: Opportunities and Risks -- Session

Chair: Alberto Grignolo, Ph.D., Corporate Vice President and General

Manager, PAREXEL Consulting

(9:00)

-- Combination Products: Drug or Device? -- Cecil Nick, Principal

Consultant, PAREXEL Consulting

(9:00)

-- Data Driven Patient Recruitment: Tools for Early Planning and

Predictive Management (poster presentation) -- Petra Moll, Associate

Director, Clinical Operations, Clinical Research Services

Wednesday, March 5

-- Meeting Patient En
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- InferMed , s ... will augment ... olutions suite   Elsevier , a ... services, announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ... therapeutics that address unmet medical needs in women,s ... will present at the Cantor Fitzgerald Inaugural ... 2015Time: , 4:45 PM EDTLocation: , Le Parker ... , www.juniperpharma.com, under  ,Investor, or  click ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... CAMBRIDGE, Mass., Aug. 25 Peptimmune, Inc., ... a clinical trial to evaluate the safety, tolerability, pharmacokinetics, ... Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide ... autoimmune diseases. , , The Phase ...
... CITY, Aug. 25 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: ... effective and affordable vaccines based on proprietary manufacturing ... it has received clearance from Health Canada to ... its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrollment ...
... , SAN MATEO, Calif., Aug. 25 ... on developing and commercializing novel pain management therapies, today announced the ... a director and Audit Committee chairman, effective August 20, 2009. Mr. ... company focused on exploiting a novel, Nobel Prize winning method of ...
Cached Biology Technology:Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/16/2015)... Fingerprint Cards has received an order of 375 ... from one of its module partners in Asia ... the third quarter 2015. The sensors will be used by ... Jörgen Lantto, CEO of FPC, comments: " This order   ... smartphone OEMs in integrating touch fingerprint sensors in   their ...
(Date:6/15/2015)... , June 15, 2015 A new ... Telstra reveals the majority of US consumers using mobile banking ... biometrics, such as fingerprint and voiceprint, instead of having to ... According to Telstra,s " Mobile Identity   -   The ... report, with smartphones now the primary channel used by Gen ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... Michigan State University researchers looking at the effects of ... calorie-restricted diet were more likely to die after being ... While research suggests inflammation associated with obesity ... the study results revealed a low-calorie diet may actually ...
... on the BP Deepwater Horizon drilling rig in the Gulf ... to understand the impact that this disaster has had on ... at a rate of approximately 53,000 barrels per day before ... study confirms that oil from the Macondo well made it ...
... is now open for the forthcoming International Polar Year ... 22-27 April 2012, Montral, Canada The IPY 2012 ... the largest and most important scientific conferences for polar ... thought-provoking panel discussions and workshops will provide the focal ...
Cached Biology News:Low-calorie diet may be harmful for bowel disease patients 2Study confirms oil from Deepwater Horizon disaster entered food chain in the Gulf of Mexico 2International Polar Year conference: From knowledge to action 2
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: